Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gibb

Showing results (261-270 of 419) with videos related to

Pageof 42
Sort By:
Plos Medicine|November 9, 2013
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling studyMarie-Quitterie Picat, Joanna Lewis, Victor Musiime, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapyAndrew Reid, Wolfgang Stöhr, A Sarah Walker, et al.
British Journal of Clinical Pharmacology|March 19, 2016
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenAndrzej Bienczak, Adrian Cook, Lubbe Wiesner, et al.
AIDS (London, England)|April 13, 2004
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcomeJ-P Aboulker, A Babiker, M L Chaix, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and TreatmentA E Ades, Fabiana Gordon, Karen Scott, et al.
AIDS (London, England)|April 14, 2011
Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapyAndrew Prendergast, Mutsa F Bwakura-Dangarembizi, Adrian D Cook, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2010
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adultsC Kityo, A S Walker, L Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and ZimbabweA Sarah Walker, Andrew J Prendergast, Peter Mugyenyi, et al.
Lancet (London, England)|November 24, 2004
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trialC Chintu, G J Bhat, A S Walker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2007
Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult careAli Judd, Katja Doerholt, Pat A Tookey, et al.
Pageof 42

Showing results (261-270 of 419) with videos related to

Sort By:
Pageof 42
Plos Medicine|November 9, 2013
Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling studyMarie-Quitterie Picat, Joanna Lewis, Victor Musiime, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapyAndrew Reid, Wolfgang Stöhr, A Sarah Walker, et al.
British Journal of Clinical Pharmacology|March 19, 2016
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenAndrzej Bienczak, Adrian Cook, Lubbe Wiesner, et al.
AIDS (London, England)|April 13, 2004
Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcomeJ-P Aboulker, A Babiker, M L Chaix, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and TreatmentA E Ades, Fabiana Gordon, Karen Scott, et al.
AIDS (London, England)|April 14, 2011
Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapyAndrew Prendergast, Mutsa F Bwakura-Dangarembizi, Adrian D Cook, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2010
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adultsC Kityo, A S Walker, L Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and ZimbabweA Sarah Walker, Andrew J Prendergast, Peter Mugyenyi, et al.
Lancet (London, England)|November 24, 2004
Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trialC Chintu, G J Bhat, A S Walker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2007
Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult careAli Judd, Katja Doerholt, Pat A Tookey, et al.
Pageof 42